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With great interest, we read the article by Rickman et al.
(2020), highlighting the link between defective phosphatidy-
lethanolamine (PE) biosynthesis and hereditary spastic para-
plegia (HSP). The cytidine diphosphate (CDP)-ethanolamine
pathway is a three-step enzymatic cascade involved in PE
biosynthesis. The rate-limiting enzyme in this pathway, etha-
nolamine-phosphate cytidylyltransferase (ET), is encoded by
PCYT2 (OMIM 618770), and biallelic variants in this gene
have been associated with a clinical spectrum of HSP (Vaz
et al., 2019; Vélez-Santamarı́a et al., 2020). Selenoprotein 1
(SELENOI) (OMIM 607915, also known as EPT1),
catalyses the final step in the biosynthesis of PE via the
CDP-ethanolamine pathway (Horibata and Hirabayashi,
2007). Biallelic variants in SELENOI/EPT1 have also been
linked to complex HSP in two families (Ahmed et al., 2017;
Horibata et al., 2018). Here, we report two additional indi-
viduals harbouring biallelic variants of PCYT2 and
SELENOI/EPT1.
Case 1 was a female, who was born as a second child to
healthy, non-consanguineous German parents after an unre-
markable pregnancy and birth. Her older sister died in
adulthood of probable myocarditis. The affected individual
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failed to thrive, and at the age of 3 years she was noted to
have severely reduced vision. At 5 years of age, early-onset
severe retinal dystrophy (EOSRD) was diagnosed. In add-
ition, bilateral cataracts were observed, and these were
treated surgically at the age of 6 years. Epilepsy with mostly
generalized tonic-clonic seizures was diagnosed at 13 years
of age, and EEG showed occipital lobe epileptiform dis-
charges. Progressive bilateral hearing loss was reported be-
ginning at age 19 years and attributed to sensorineural
damage. A muscle biopsy at age 14 years was normal (no
signs of mitochondrial disease on immunohistochemistry).
An intellectual impairment was not observed (total IQ at
low normal range, with a selective lower value for ‘word
fluid’) and the patient embarked on a university degree. At
the age of 16 years, the patient complained of gait abnor-
malities and a physical examination showed signs of cerebel-
lar ataxia with spontaneous nystagmus, ataxic gait and limb
ataxia. Although hyperreflexia was noticeable, no spasticity
was observed, and the Babinski sign was negative. No
muscle weakness or dysmorphic features were detected.
MRI of the brain demonstrated cerebellar atrophy (Fig. 1G)
and that of the spine showed atrophy of the spinal cord pre-
dominantly at the thoracic level (Fig. 1G and Supplementary
Fig. 2). The latency of the sensory evoked potential (P40) of
the tibial nerve was delayed to 53 ms on the right side; no
potential was present on the left side. At the age of 28 years,
she was found dead in the bathtub, presumably after a
seizure.
Exome sequencing on the proband’s DNA was performed
as previously described (Wagner et al., 2019). Two heterozy-
gous variants in PCYT2 (NM_001184917.2:
c.1112 + 1G4A; and c.743T4A, p.(Val230Glu) were iden-
tified. Sanger sequencing confirmed both variants in the
index and carriership of one variant each in both parents
(Fig. 1A and Supplementary Fig. 1). The canonical splice
variant was absent from the Genome Aggregation Database
(gnomAD), Queen Square Genome database of 16 000
exomes and the Munich in-house database of 21 000
exomes (Supplementary Table 1). In silico tools strongly pre-
dicted an alteration of splicing (Human Splicing Finder: –
165%). Subsequent cDNA analysis conducted as previously
described (Krenn et al., 2019) from fibroblast RNA revealed
the presence of an additional longer splice product in com-
parison with a control sample on gel electrophoresis
(Fig. 1I). It should be noted, however, that this experiment
did not exclude the expression of correctly spliced RNA
from the respective allele. Subsequent Sanger sequencing of
the two bands revealed that the splice variant resulted in the
retention of intron 12 and introduction of a premature stop
codon after 17 amino acids (Fig. 1K).
The missense variant was absent from our in-house data-
bases and seen only once in a heterozygous state in 251 240
gnomAD alleles. In silico tools consistently predicted the
missense variant to be deleterious (PolyPhen-2: 0.987, SIFT:
0, CADD: 32, M-CAP: 0.644) (Supplementary Table 1).
This altered amino acid was highly conserved (Fig. 1E) and
located within the second cytidylyltransferase (CTP) catalytic
domain of PCYT2 (Fig. 1C) (Pavlovic et al., 2014) immedi-
ately adjacent to the p.His226X227Gly228His229 catalytic
motif. Molecular Operating Environment version 2019.0102
using the Amber10: EHT force field was used for molecular
dynamic simulation to predict the effect of p.(Val230Glu) on
PCYT2 structure and function. The ligand binding pocket of
p.(Val230Glu) was less open than the wild-type and resulted
in CTP being far less likely to dock in its normal binding
site in the p.(Val230Glu) variant. In addition, there were
alterations between preferred amino acid residue binding
within the catalytic site for both CTP and phosphoethanol-
amine for the p.(Val230Glu) variant compared with the
wild-type enzyme (Fig. 1N). The p.(Val230Glu) change was
immediately adjacent to the PCYT2 catalytic motif and mo-
lecular dynamics modelling predicted deficient substrate
binding for the p.(Val230Glu) variant.
Case 2 was a 5-year-old male, who was born full-term to
consanguineous parents of Balochi ethnicity from Iran. He
was born after an unremarkable pregnancy with a below-
average birth weight and occipitofrontal circumference (15th
percentile). The disease manifested though remarkable
growth failure and profound psychomotor retardation. He
failed to sit or ambulate independently or develop speech
and non-verbal communication skills. From the early post-
natal period, he developed daily recurring generalized tonic-
clonic seizures and paroxysmal tonic upgaze. Phenobarbital
significantly reduced the frequency of the seizures to one per
week, and he has been seizure-free for the last 4 months.
Because of the lack of growth and prominent feeding diffi-
culties, his current body mass index is 11.2 (the 1st percent-
ile). Additionally, he had severe microcephaly, scoliosis and
congenital cataract. There are signs of facial dysmorphism
including large, low-set protruding ears, hypertelorism and a
wide nasal bridge (Fig. 1H).
His neurological examination revealed bilateral visual im-
pairment, paroxysmal tonic upgaze and dysphagia together
with central hypotonia, severe appendicular spasticity and
distal and proximal flexion contractures in the upper limbs
(Supplementary Video 1). In addition, there was hyperexten-
sion of the knees, external deviation of the feet, brisk tendon
reflexes, reduced power, and wasting of muscles (Fig. 1H).
While his metabolic screening was unrevealing, brain MRI
showed cerebral hemispheric, pontine, medullary and cere-
bellar atrophy with extensive hypomyelination and ventricu-
lomegaly (Fig. 1J). EEG showed bilateral posterior
abnormalities in the context of artefactual activity.
Electrophysiology studies and ophthalmological examination
were not available.
To identify the genetic cause of the disease in the affected
individual, exome sequencing on DNA extracted from the
proband’s leucocytes and variant filtering were performed as
previously described (Makrythanasis et al., 2018). A novel
homozygous missense variant in exon 3 of SELENOI/EPT1
c.134C4T, p.(Pro45Leu) (NM_033505.3) residing within a
23.7 Mb region of homozygosity was identified. The
p.(Pro45Leu) variant was located in a highly conserved
SELENOI/EPT1 protein in the N-terminal region of an
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Figure 1 Genetic and clinical summary of the investigated cases with functional characterization of SELENOI/EPT1
p.(Pro45Leu) deficiency and molecular modelling of the PCYT2 p.(Val230Glu) variant. (A) Family tree for Case 1. Square = male; circle
= female; filled symbol = affected individual; open symbols = unaffected carriers; WT = wild-type allele. (B) Family tree for Case 2. Square = male;
circle = female; filled symbol = affected individual. The double line indicates consanguinity. (C) Domain structure of PCYT2b with localization of
the disease-associated variants. PCYT2b splicing results in the deletion of residues 180–197 from the central linked segment (Pavlovic et al., 2014).
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endoplasmic reticulum luminal-facing domain (CADD score
of 26.9 and high conservation GERP score of 5.96) (Fig. 1D
and F). The variant was absent from gnomAD and predicted
to be probably damaging (PolyPhen-2) or deleterious/damag-
ing (PROVEAN) (Supplementary Table 1).
To determine the functional significance of the variant, we
assessed the effect of p.(Pro45Leu) on SELENOI/EPT1 activ-
ity in a yeast strain (Supplementary material). Cells express-
ing SELENOI/EPT1 p.(Pro45Leu) displayed a significant
increase in radiolabel associated with CDP-ethanolamine
compared with wild-type SELENOI/EPT1and a decrease in
radiolabel associated with the downstream lipids PE and
phosphatidylcholine (Fig. 1L). This was consistent with an
impairment in CDP-ethanolamine pathway activity at the
SELENOI/EPT1-catalysed step. Western blots in yeast
showed SELENOI/EPT1and the mutant version exhibited a
projected molecular weight of 46 kDa and were detected at
a similar level (Fig. 1M).
Subcellular lipidome imbalance has been shown to play an
important role in the mechanisms underlying motor neuron
diseases (Rickman et al., 2020). Numerous genes involved in
lipid metabolism have already been linked to HSP (Ahmed
et al., 2017). PCYT2 and SELENOI/EPT1 are among the
recently characterized HSP-associated genes and are current-
ly reported only in a few families. PCYT2 has been reported
in six independent families presenting with a phenotypic
spectrum ranging from pure to complex forms of HSP (Vaz
et al., 2019; Vélez-Santamarı́a et al., 2020) (Table 1).
Impaired vision with nystagmus and seizures were among
the frequent symptoms in reports of PCYT2. Variable
features have included hearing loss, bilateral cataracts and
ataxia. While brain MRI was unremarkable in one PCYT2
case with pure HSP, other cases showed progressive, non-ex-
tensive T2-weighted white matter hyperintensities with cere-
bral or cerebellar atrophy.
Case 1 presented with a complex and progressive pheno-
type partly overlapping with the previously reported
PCYT2-related HSP cases including visual impairment, bilat-
eral cataract, sensorineural deafness and seizures (Vaz et al.,
2019; Vélez-Santamarı́a et al., 2020). In this case, we show
that confirmed EOSRD could be the early manifestation and
a dominant feature of PCYT2-associated disorder. In con-
trast with the previous PCYT2 reports, where cerebellar
ataxia was a part of complex HSP in two affected individu-
als, Case 1 did not express spastic paraplegia, and severe
cerebellar ataxia was the sole locomotor feature. This is not
surprising, as various genes including those involved in
phospholipid metabolism have been shown to present with
HSP at one end of the disease continuum and ataxia at the
other. Because of the overlapping phenotypes and shared
disease mechanisms, these genes have been proposed to
cause the ataxia-spasticity disease spectrum (ASS) (Synofzik
and Schüle, 2017). It should be acknowledged, however,
that the suggested association between the compound het-
erozygous PCYT2 variants in Case 1 and ASS would have
been strengthened if we had quantified the wild-type and
misspliced mRNA resulting from the splice variant
c.1112 + 1G4A or performed lipidomics studies.
SELENOI/EPT1 was first reported in Brain by Ahmed
et al. (2017) in four siblings of Omani origin with a core
Figure 1 Continued
PCYT2 protein is predicted to have two catalytic domains. The yellow and blue box indicate the N-catalytic domain and C-catalytic domain, re-
spectively. Pathogenic variants reported in previous papers and identified in this study are shown in black and red, respectively. (D) The predicted
transmembrane and cytoplasmic domains of the SELENOI/EPT1 protein (Q9C0D9). The SELENOI/EPT1 protein (NM_033505.3) contains 397
amino acid residues spanning the predicted six cytoplasmic and 10 transmembrane domains. The yellow box indicates the endoplasmic reticulum
luminal facing domain. The green box shows the CDP-alcohol phosphotransferase domain. Blue boxes illustrate other cytoplasmic domains and
orange boxes show transmembrane domains. Pathogenic amino acid changes reported in previous papers and identified in this study are shown
in black and red, respectively. (E) Protein multiple sequence alignment showing that p.Val230 is located in the highly-conserved PCYT2 protein
region. (F) Protein multiple sequence alignment showing that p.(Pro45) is located in the highly-conserved SELENOI/EPT1protein region. (G)
Brain and cervical/thoracic spinal cord MRI images from Case 1. The T1-weighted axial scan of the brain on the left shows cerebellar atrophy. The
T2-weighted sagittal scan of the spinal cord on the right shows spinal cord atrophy at the level of the thoracic segment. (H) Clinical photos from
Case 2. The top image demonstrates a profoundly disabled patient with short and malnourished stature, distal and proximal flexion contractures
in upper limbs, hyperextension of the knees and external deviation of the feet. The bottom images show tonic upgaze, dysmorphic facial features
such as large protruding ears, hypertelorism and a wide nasal bridge. Feeding occurs through the nasogastric tube. (I) Gel electrophoresis from
cDNA analysis of the PCYT2 c.1112 + 1G4A variant showing two forms of PCYT2 splice products of 226 and 347 bp, respectively in Case 1. (J)
Brain MRIs from Case 2 showing widespread T2-weighted white matter hyperintensities with cerebral and cerebellar atrophy on the left and mid-
dle images. The image on the right depicts brainstem and cerebellar atrophy. (K) Electropherogram showing that PCYT2 c.1112 + 1G4A splice
variant results in the retention of intron 12 and the introduction of a premature stop codon after 17 amino acids. (L) Incorporation of radiola-
belled ethanolamine into the metabolites of the CDP-ethanolamine pathway. Yeast cells that had their endogenous EPT1 gene inactivated were
transformed with a plasmid expressing human SELENOI/EPT1, and SELENOI/EPT1 p.(Pro45Leu) and an empty vector (EV). Cells were incubated
with radiolabelled ethanolamine for 1 h, the metabolites of the CDP-ethanolamine pathway were separated by thin-layer chromatography and
the incorporation of radiolabel into each CDP-ethanolamine pathway metabolite was determined by scintillation counting. (M) Western blot
showing the expression of human SELENOI/EPT1 and SELENOI/EPT1 p.(Pro45Leu) in yeast cells. (N) Protein modelling predicts that the PCYT2
p.(Val230Glu) variant affects the overall structure of the substrate binding pocket and has a strong negative effect on binding of CTP (shown) and
phosphoethanolamine (not shown) to the active site of PCYT2. Blue indicates CTP binding to wild-type; green indicates CTP binding to
p.(Val230Glu).
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phenotype similar to that of our case, albeit with a milder
course (Table 1). These siblings were verbal and had grad-
ually regressed after delayed achievements of developmental
milestones. The spasticity was limited to the lower limbs in
all but one sibling. They did not have clinically expressed
seizures, but cleft palate, bifid uvula, retinal abnormalities
and neurophysiological evidence of a demyelinating periph-
eral neuropathy were among their distinguishable signs.
Ocular examination revealed pigmentary retinopathy and
rod-cone dysfunction. The second family with SELENOI/
EPT1-linked complex HSP was reported by Horibata et al.
(2018) and had a spectrum of main features closer to those
seen in our case, although with additional signs such as sen-
sorineural deafness and roving eye movements (Table 1).
Although there were conspicuously overlapping core symp-
toms between Case 2 and the aforementioned SELENOI/
Table I Summary of genetic findings and clinical features of SELENOI/EPT1 and PCYT2 cases



































Age (years)/sex 5/M 1.9–15/3M, 1F 4/M 26/F 2.5–20/4M, 1F 7 and 46/2M
Consanguinity + + + – + (4) + (1)
Development
Global DD + (S) + + (S) – + (5), 1S + (1)
ID + (P) + + – + (5), 2P + (1S)
Poor growth + (S) + + + + + (1S)
Speech impairment + (S) + (3) + + a + –
Regression – + (2) – – + –
HSP-associated symptoms
Progressive microcephaly + (S) + (2) + – + (1) –
Dysmorphic features + FD (4) CP, HP, BU HP, BU – –(5) + (1)
Seizures GTCS – TCS + TCS, FS + (1)
Visual impairment + + (2) + + + (4) + (1)
Sensorineural deafness – – + + + (1) –
Oculomotor abnormalities + TU – ER – – –
Peripheral neuropathy NA + (1) NA – NA NA
Cerebellar ataxia – – – + + (1) + (1)
Bilateral cataract + – – + – + (1)
Scoliosis + – – – – –
Neurological examination
Nystagmus – – + + + (4) + (1)
Dysphagia + – – – – –
Spasticity UL, LL + (LL, UL) + (3 LL), 1 (UL, LL) + (UL, LL) – + (LL) + (1 LL), (1 UL,
LL)
Hyperreflexia + + + + + +
Hypotonia – – Truncal – – –
Joint contractures + NA + – NA –
Investigations
Brain MRI WMH (S), CA,
CRA, BSA
WMH WMH (S), CA,
CRA, TCC
CRA WMH, CA, CRA WMH (1)
Ocular examination NA RP (2), CRD (1) Absent VEP; normal
ERG
SRD OA (1) OA (1)
BS = brainstem atrophy; BU = bifid uvula; CA = cerebral atrophy; CP = cleft palate; CRA = cerebellar atrophy; CRD = cone-rod dysfunction; DD = developmental delay; ER =
eye roving; ERG = electroretinography; F = female; FD = facial dysmorphism; FS = focal seizures; GTCS = generalized tonic-clonic seizures; HP = high arched palate; HSP = her-
editary spastic paraplegia; ID = intellectual disability; LL = lower limbs; M = male; NA = not available; OA = optic atrophy; P = profound; RP = retinitis pigmentosa; S = severe;
SRD = severe retinal dystrophy; TCC = thin corpus callosum; TCS = tonic-clonic seizures; TU = tonic upgaze; UL = upper limbs; VEP = visual evoked potentials; WMH = T2
white matter hyperintensity.
aImpaired word fluidity.
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EPT1 reports, the spectrum of the SELENOI/EPT1 phenotype
seemed to be more severe in the present case. Features includ-
ing severe growth failure, unachieved motor milestones and
communication skills, severe dysphagia, congenital cataract
and facial dysmorphism distinguished our case from the previ-
ously published SELENOI/EPT1 families. Cerebellar atrophy,
brain stem atrophy and extensive hypomyelination were not
observed in the family described by Ahmed et al. (2017), but
these features were prominent in Case 2 and the report by
Horibata et al. (2018). In addition, tonic upgaze was a pecu-
liar feature in our report that could putatively be ascribed to
the observed degree of hypomyelination, pontine/medullary
and cerebellar atrophy (Hills et al., 2013; Blumkin et al.,
2015).
Of note was the overlapping progressive phenotype be-
tween PCYT2 and SELENOI/EPT1. Both expressed a com-
parable spectrum of associated symptoms and severity,
suggesting the importance of the CDP-ethanolamine path-
way in the mechanism of complex neurodegenerative disor-
ders. PCYT2 reports have unequivocally demonstrated how
ascertaining more cases might expand the disease phenotype
towards the milder end of the spectrum to pure HSP, and
suggested the possibility of a predominant cerebellar ataxia
phenotype with no spastic paraplegia as in Case 1.
Visual impairment was a common feature for almost all
affected individuals with biallelic variants in PCYT2 and
SELENOI/EPT1. Ocular phenotyping revealed retinal path-
ology and optic atrophy, suggesting a particular susceptibil-
ity of retinal cells to the imbalance in CDP-ethanolamine
and related pathways (Rickman et al., 2020).
In summary, we have presented further families with bial-
lelic variants in PCYT2 and SELENOI/EPT1, thereby
expanding the clinical spectrum of CDP-ethanolamine-
related disorders. Additionally, we have highlighted the re-
markable clinical overlap between PCYT2 and SELENOI/
EPT1 with retinal involvement being the common sign.
Finally, we have drawn attention to the possibility of a
broad ASS, which may result from defective PE biosynthesis.
Awareness of a possible ASS phenotype and further reports
will improve our understanding of the clinical spectrum and
disease continuum of emerging CDP-ethanolamine-related
disorders.
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